Media

Mumbai, Naples, August 29, 2024: Global pharma major Lupin Limited (Lupin) today announced the launch of Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials in the United States, after Lupin’s alliance partner, ForDoz Pharma Corporation, USA (ForDoz) received an approval for its ANDA from the United States Food and Drug Administration (U.S. FDA).

Doxorubicin Hydrochloride Liposome Injection 20 mg/10 mL (2 mg/mL) and 50 mg/25 mL (2 mg/mL) Single-Dose Vials is a generic equivalent of Doxil® (Liposomal), of Baxter Healthcare Corporation, indicated for the treatment of Ovarian Cancer, Acquired Immune Deficiency Syndrome (AIDS)-related Kaposi’s Sarcoma, and Multiple Myeloma.

Doxorubicin Hydrochloride Liposome Injection (RLD Doxil® (Liposomal)) had an estimated annual sales of USD40.9 million in the U.S. (IQVIA MAT June 2024).

Lupin Limited is a global pharmaceutical leader headquartered in Mumbai, India, with products distributed in over 100 markets. Lupin specializes in pharmaceutical products, including branded and generic formulations, complex generics, biotechnology products, and active pharmaceutical ingredients. Trusted by healthcare professionals and consumers globally, the company enjoys a strong position in India and the U.S. across multiple therapy areas, including respiratory, cardiovascular, anti-diabetic, anti-infective, gastrointestinal, central nervous system, and women’s health. Lupin has 15 state-of-the-art manufacturing sites and 7 research centers globally, along with a dedicated workforce of over 22,000 professionals. Lupin is committed to improving patient health outcomes through its subsidiaries – Lupin Diagnostics, Lupin Digital Health, and Lupin Manufacturing Solutions.

www.lupin.com or follow us on LinkedIn https://www.linkedin.com/company/lupin

For further information or queries please contact –

Doxil ® is a registered trademark of Baxter International Inc.